Indexed keywords
ANTIDEPRESSANT AGENT;
ANXIOLYTIC AGENT;
BENZODIAZEPINE DERIVATIVE;
MIRTAZAPINE;
SEROTONIN UPTAKE INHIBITOR;
ZOPICLONE;
ADULT;
AGED;
ARTICLE;
BODY MASS;
BODY WEIGHT;
BODY WEIGHT DISORDER;
CENTRAL NERVOUS SYSTEM DISEASE;
CLINICAL ASSESSMENT;
CLINICAL GLOBAL IMPRESSION SCALE;
CLINICAL TRIAL;
DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS;
DIZZINESS;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG FATALITY;
DRUG SAFETY;
DRUG TOLERABILITY;
EDEMA;
FATIGUE;
FEMALE;
GASTROINTESTINAL DISEASE;
HUMAN;
INCREASED APPETITE;
MAJOR CLINICAL STUDY;
MAJOR DEPRESSION;
MALE;
MENTAL DISEASE;
METABOLIC DISORDER;
MONTGOMERY ASBERG DEPRESSION RATING SCALE;
MULTICENTER STUDY;
NUTRITIONAL DISORDER;
OBSERVATIONAL STUDY;
OPEN STUDY;
PATIENT SELECTION;
PERIPHERAL NEUROPATHY;
POPULATION RESEARCH;
PRESCRIPTION;
PRIMARY MEDICAL CARE;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
PSYCHIATRIC DEPARTMENT;
RESTLESS LEGS SYNDROME;
SLEEP;
SUICIDE ATTEMPT;
SWEDEN;
SYMPTOMATOLOGY;
VITAL SIGN;
XEROSTOMIA;
ADOLESCENT;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTIDEPRESSIVE AGENTS, TRICYCLIC;
BODY MASS INDEX;
DEPRESSION;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG EVALUATION;
DRUG TOXICITY;
FEMALE;
HUMANS;
LONGITUDINAL STUDIES;
MALE;
MIANSERIN;
MIDDLE AGED;
PROSPECTIVE STUDIES;
PSYCHIATRIC STATUS RATING SCALES;
RETROSPECTIVE STUDIES;
SWEDEN;
TIME FACTORS;
TREATMENT OUTCOME;
1
4444356636
Therapeutic Drug Monitoring of psychotropic drugs. TDM 'nouveau'
Bengtsson F. 2004. Therapeutic Drug Monitoring of psychotropic drugs. TDM 'nouveau'. Ther Drug Monit 26: 145-151.
(2004)
Ther Drug Monit , vol.26
, pp. 145-151
Bengtsson, F.1
2
0004173088
Springer Verlag. New York
Good P. 2000. Permutation Tests. Springer Verlag. New York.
(2000)
Permutation Tests
Good, P.1
3
0034924791
Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features
Guelfi JD, Ansseau M, Timmerman L, et al. 2001. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 21: 425-431.
(2001)
J Clin Psychopharmacol , vol.21
, pp. 425-431
Guelfi, J.D.1
Ansseau, M.2
Timmerman, L.3
5
0033884020
Recruitment of depressive patients for a controlled clinical trial in psychiatric practice
Haberfellner EM. 2000. Recruitment of depressive patients for a controlled clinical trial in psychiatric practice. Pharmacopsychiatry 33: 142-144.
(2000)
Pharmacopsychiatry , vol.33
, pp. 142-144
Haberfellner, E.M.1
6
33646340846
The use of mirtazapine in primary care in Germany
Kreutzenbeck H-J, Zivkov M. 1998. The use of mirtazapine in primary care in Germany. Eur Neuropsychopharmacol 8(Suppl. 2): 185.
(1998)
Eur Neuropsychopharmacol , vol.8
, Issue.SUPPL. 2
, pp. 185
Kreutzenbeck, H.-J.1
Zivkov, M.2
7
33646366831
A naturalistic study of mirtazapine in the German psychiatric practice
May F, Pattenier AM. 1998. A naturalistic study of mirtazapine in the German psychiatric practice. Eur Neuropsychopharmacol 8(Suppl. 2): 146.
(1998)
Eur Neuropsychopharmacol , vol.8
, Issue.SUPPL. 2
, pp. 146
May, F.1
Pattenier, A.M.2
8
0035025633
Are antidepressants overrated? A review of methodological problems in antidepressant trials
Moncrieff J. 2001. Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis 189: 288-295.
(2001)
J Nerv Ment Dis , vol.189
, pp. 288-295
Moncrieff, J.1
9
0018425438
A new depression scale designed to be sensitive to change
Montgomery SA, Åsberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
(1979)
Br J Psychiatry , vol.134
, pp. 382-389
Montgomery, S.A.1
Åsberg, M.2
11
0036163839
A reevaluation of the exclusion criteria used in antidepressant efficacy trials
Posternak MA, Zimmerman M, Keitner GI, Miller IW. 2002. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 159: 191-200.
(2002)
Am J Psychiatry , vol.159
, pp. 191-200
Posternak, M.A.1
Zimmerman, M.2
Keitner, G.I.3
Miller, I.W.4
12
23244463878
Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder. A six months therapeutic drug monitoring study
Reis M, Prochazka J, Sitsen A, Ahlner J, Bengtsson F. 2005. Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder. A six months therapeutic drug monitoring study. Ther Drug Monit, 27(4): 469-477.
(2005)
Ther Drug Monit , vol.27
, Issue.4
, pp. 469-477
Reis, M.1
Prochazka, J.2
Sitsen, A.3
Ahlner, J.4
Bengtsson, F.5
13
0035200581
Efficacy of mirtazapine for prevention of depressive relapse: A placebo-controlled double-blind trial of recently remitted high-risk patients
Thase ME, Nierenberg AA, Keller MB, et al. 2001. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 62: 782-788.
(2001)
J Clin Psychiatry , vol.62
, pp. 782-788
Thase, M.E.1
Nierenberg, A.A.2
Keller, M.B.3
14
33646366304
Efficacy and tolerability of mirtazapine in everyday clinical practice in the Netherlands
Timmerman L, Helsdingen JTH, Boumans AAJ. 1998. Efficacy and tolerability of mirtazapine in everyday clinical practice in the Netherlands. Eur Neuropsychopharmacol 8(Suppl. 2): S147.
(1998)
Eur Neuropsychopharmacol , vol.8
, Issue.SUPPL. 2
Timmerman, L.1
Helsdingen, J.T.H.2
Boumans, A.A.J.3
15
0031919505
Inflationary tendencies in judging the yield of depression research
van Praag HM. 1998. Inflationary tendencies in judging the yield of depression research. Neuropsychobiology 37: 130-141.
(1998)
Neuropsychobiology , vol.37
, pp. 130-141
van Praag, H.M.1
